Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Immunotherapy. 2015 Jun 22;7(6):631–640. doi: 10.2217/imt.15.18

Figure 1. Radioimmunotherapy of CasKi tumors with 188Rhenium-C1P5 and 188Rhenium-TVG-701Y monoclonal antibodies.

Figure 1

(A) Average change in tumor volume (V2 – V0/V0) over time among treatment groups was compared with untreated CasKi control tumors. (B) WBC counts during the observation period. X-axis shows 106 WBC per ml; (C) platelet counts during the observation period.

*p < 0.05; **p < 0.005; ***p < 0.0005.

188Re: 188Rhenium; WBC: White blood cell.